Memo Therapeutics AG (MTx)

https://www.memo-therapeutics.com

Memo Therapeutics AG (“MTX”) is a clinical-stage biopharma company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. Memo’s pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), as well as undisclosed immuno-oncology targets. The pipeline derives from MTx’s industry-leading throughput and functional screening capabilities, which can cover the entire antibody repertoire. Using its immortal cell libraries and unique nano droplet technology, MTx identifies and isolates the most potent antibodies based on functionality at an unprecedent rate, including discovering ultra-rare antibodies that competing technologies fail to identify. MTx is a private company located in Schlieren / Zurich, Switzerland. *

	Start	2012-11-29 splitoff
	Predecessor	ETH Zürich (ETHZ)
	Industry	MemoMAB™ antibody discovery platform
	Industry 2	AntiBKV (Memo Therapeutics)
	Person	Fischer, Karsten (Memo Therapeutics 201806–202311 CEO before BioMedPartners + WestLB LEFT 11/23)
	Person 2	Esslinger, Christoph (Memo Therapeutics AG 202011 CSO + Co-Founder formerly CEO)

	Region	Schlieren ZH
	Country	Switzerland
	Street	27 Wagistr.
	City	8952 Schlieren ZH
	Tel	+41-44-515-9140
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Memo Therapeutics AG. (1/24/23). "Press Release: Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients". Schlieren.

		Record changed: 2023-11-29